CERS Stock — Cerus Corp

Up next

Next earnings release

Nov 2, 2026 Announced · in 2 wks

Next earnings call

Nov 2, 2026 Scheduled · in 2 wks

Latest filing: 10-Q

filed Jul 30, 2026

Q2 2026 earnings call transcript

call held Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$249.22M

Trailing 12 months

Net income (TTM)

−$6.78M

Trailing 12 months

Revenue growth YoY

+9.5%

Year over year

Operating margin

-3.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-0.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$46.94M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.8%

Year over year · more shares

Price change (1Y)

+45.1%

Trailing year

Short interest

8.7%

Latest settlement · 8.0 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

· $9.53M −$17.08M '17 Q2 · $10.80M −$13.42M '17 Q3 ▲61.9% $15.42M −$13.28M '18 Q2 ▲42.6% $15.40M −$14.19M '18 Q3 · $43.24M −$7.72M '25 Q1 · $52.45M −$5.71M '25 Q2 ▲24.1% $53.66M −$1.64M '26 Q1 LATEST ▲9.5% $57.44M −$2.94M '26 Q2

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 18.4 · elevated Equity put/call 0.55

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −9%

below

Price vs 50-day avg −13%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 44%

mid-range

Momentum

relative strength

Strong

1-month return −13%

trailing

6-month return +13%

trailing

YTD return +8%

this year

Relative strength +5%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $3 › 200d $2 — 50d above 200d

Institutional flow Distributing

16 of 186 funds reported for Sep 30 · net -864.3K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

8.72% of float · ▼ -2.3% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

186 holders — near 3-yr high, broad support

Squeeze score 55

elevated · 0–100

Fundamentals

Excellent

Revenue growth +31%

Y/Y

Gross margin 33%

expanding

EPS growth +27%

Y/Y

Free cash flow $1.1M

Balance sheet $24.1M

net cash

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −38%

past year

ATR 4.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Jul 30, 2026

Product revenue · full-year 2026 Raised $229M – $231M

Apr 30, 2026 $227M – $231M Jul 30, 2026 $229M – $231M

IFC revenue · full-year 2026 Raised $23M – $25M

Apr 30, 2026 $22M – $24M Jul 30, 2026 $23M – $25M

Prior guidance period ended · from the 8-K filed Nov 6, 2025

Product revenue · full-year 2025 $202M – $204M

IFC revenue · full-year 2025 $16M – $17M

Guided vs delivered · last 3 settled

Full year 2025 product revenue full year 2025

guided $200M – $203M

guided $200M – $203M $233.8M Beat +16.0%

Product revenue full year 2021

guided $118M – $122M

guided $118M – $122M $159.52M Beat +32.9%

Product revenue this year

guided $89M – $93M

guided $89M – $93M $114.25M Beat +25.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−9% Bearish

Price vs 50-day avg

−13% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

44% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $3 › 200d $2 — 50d above 200d

Institutional flow Distributing

16 of 186 funds reported for Sep 30 · net -864.3K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

8.72% of float · ▼ -2.3% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

186 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $2 · 44% Range high $3

vs 200-day avg -9% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash used in operations	$2.7M	Q2 2026	—
Change in Calculated Number of Treatable Platelet Doses - North America	6%	Six Months Ended June 30, 2026 vs. 2025	—
Change in Calculated Number of Treatable Platelet Doses - Worldwide	6%	Six Months Ended June 30, 2026 vs. 2025	—
Non-GAAP Adjusted EBITDA non-GAAP	$7M	First half of 2026	—
Platelet Kit Growth - International	9%	Six Months Ended June 30, 2026 vs. 2025	—
Platelet Kit Growth - North America	4%	Six Months Ended June 30, 2026 vs. 2025	—
Platelet Kit Growth - Worldwide	5%	Six Months Ended June 30, 2026 vs. 2025	—
Product Gross Margin	51.4%	Q2 2026	—
Product Gross Profit	$29.5M	Q2 2026	—
Total IFC* Demand Growth (including kits and finished therapeutic doses)	50%	Six Months Ended June 30, 2026 vs. 2025	—
U.S. IFC sales	$6.7M	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CERS Cerus Corp this stock	$447.39M	+7.8%	+30.7%	—	8.7%
ABT Abbott Laboratories	$179.20B	-16.9%	+5.7%	33.3	0.8%
MDT Medtronic plc	$118.67B	-3.4%	+8.4%	22.9	3.1%
SYK Stryker Corp	$114.28B	-15.2%	+11.2%	30.9	1.5%
BSX Boston Scientific Corp	$66.02B	-52.8%	+12.5%	18.4	2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

186

% held: 74.3%
Reported: 16 of 186
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

142

View

Short & Settlement

Short Interest Falling

Shares short

17.6M

Days to cover: 8.0d
Change: -414.4K sh

View

Short Volume

Short vol %

67%

As of: Oct 19, 2026

Short Total

View

Fails to Deliver

FTD shares

541

Value: $1.5K
As of: Aug 26, 2026

View

Off-Exchange

Off-exchange %

36.0%

Week of: Sep 14, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$233.8M

Net income (FY): $-15.6M
EPS diluted: $-0.08

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 30, 2026
This year: 14

View

Proposed Sales

Value

$89.5K

Shares: 30.0K
Filed: Aug 17, 2026

View

Earnings & Events

Webcasts Upcoming

Next webcast

Nov 2, 2026

Last webcast: Jul 30, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
CERS	-1.8%	-13.3%	+12.7%	-6.7%	+7.8%
SPY	-1.5%	-0.9%	+7.7%	+0.5%	+12.4%
vs SPY	-0.3%	-12.4%	+5.0%	-7.2%	-4.6%

CERS · Cerus Corp

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance